Lectin Labs LTD Information

The Company is a development stage pharmaceutical company based in Carson City, Nevada. Operating in a 5,000 square foot research and development facility, the Company has six issued U.S. patents, two international patents, and numerous counterpart applications pending in the U.S. and many countries. Lectin's initial product, NutraLec®, is a clinically tested functional nutraceutical containing a lectin which neutralizes Helicobacter pylori, the pathogen residing in the stomach which is principally responsible for gastritis, ulcer disease, and stomach cancer. A more potent form of this product, PhytoCAM™ Ulcer, is being developed as a prescription drug. Much of Lectin's focus is on the development of products for other gastrointestinal diseases and the prevention of sexually transmitted diseases (STDs): NutraLec II, also a functional nutraceutical containing lectins, would neutralize pathogens responsible for "soldier diarrhea," thereby providing warfighters with improved gastrointestinal health while in the field; PhytoCAM HIV, PhytoCAM VM (vaginal microbicides), and PhytoCAM Condom utilize single or multiple lectins targeted at HIV/AIDS, chlamydia, and gonorrhea. The company has also identified lectins for protection against genital herpes, syphilis, and chancroid. A particular benefit of the vaginal microbicides is that they will provide protection otherwise unavailable for women - who tend to be more vulnerable to STDs than men.